Benjamin Hohl

CHIEF FINANCIAL OFFICER

Benjamin Hohl (CHIEF FINANCIAL OFFICER) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Enliven Therapeutics, Inc. (ELVN). The largest single filing was $296K of ELVN (10,000 sh × $29.58, as filed), executed Mar 6.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 5 sells

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$1.3M

shares × price, as filed

Last traded

Sep 17

Filed yesterday

Median ADV $83.7M across their filed names

Open performance→

Volume by month

Buys $0 Sells $1.9M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 5 filings

Sector per market data · by filing · past 12 months

Most traded names

ELVN

Enliven Therapeutics, Inc. ELVN · 0 buys · 9 sells 9 filings

Recent filings

ELVNSALE Enliven Therapeutics, Inc. View filing → $288K
5,729 sh across 2 lots
Exec Sep 17
Filed Sep 21 · 5:23 PM ET ELVNSALE Enliven Therapeutics, Inc. View filing → $270K
4,630 sh × $58.35
Exec Aug 17
Filed Aug 19 · 4:17 PM ET ELVNSALE Enliven Therapeutics, Inc. View filing → $275K
5,202 sh across 2 lots
Exec Jul 17
Filed Jul 21 · 5:24 PM ET ELVNSALE Enliven Therapeutics, Inc. View filing → $149K
3,401 sh × $43.86
Exec Jun 17
Filed Jun 22 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. View filing → $296K
10,000 sh × $29.58
Exec Mar 6
Filed Mar 10 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. View filing → $105K
4,250 sh × $24.78
Exec Nov 27 2024
Filed Dec 2 2024 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. View filing → $160K
5,600 sh × $28.49
Exec Oct 28 2024
Filed Oct 30 2024 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. View filing → $281K
10,218 sh × $27.51
Exec Oct 4 2024
Filed Oct 8 2024 · 5:30 PM ET More filings →